Ribociclib (Kisqali®) From the NATALEE Trial with 5-Year Update

Mechanism of Action (CDK4/6 inhibition in HR+ disease):
- Core biology (why surgeons should care):
  - Ribociclib is a selective CDK4/6 inhibitor:
    - Blocks Cyclin D + CDK4/6 → RB phosphorylation → G1→S transition
    - At baseline, a breast cancer cell moves from G1 → S phase (DNA replication) only if a key checkpoint is passed
    - The core engine – Cyclin D + CDK4/6 = active complex:
      - This complex’s job is to turn OFF the brake (RB protein)
    - The critical step:
      - RB (retinoblastoma protein) normally acts as a brake
      - When phosphorylated → RB becomes inactive
      - This releases E2F transcription factors
      - E2F turns on genes needed for DNA synthesis (S phase)
    - 👉 So – Active CDK4/6 = cell allowed to divide
    - CDK4/6 Inhibitors:
      - Results in cell-cycle arrest in luminal (ER+) tumor cells
  - Key downstream effects:
    - Prevents proliferation of ER-driven clones
    - Enhances endocrine therapy sensitivity (synergistic with AI)
    - May reduce micrometastatic outgrowth → recurrence prevention
- Clinical interpretation:
  - Not cytotoxic → cytostatic disease control
  - Most impactful in:
    - Luminal A/B biology
    - Late recurrence–prone disease:
      - Rationale for long-duration adjuvant use (3 years)
NATALEE Trial Design (context for surgeons):
- Phase III randomized control trial:
  - ~ 5100 patients
  - Population:
    - HR+ / HER2− early breast cancer
    - Stage II to III:
      - Including selected N0 high-risk
  - Treatment:
    - Ribociclib (400 mg, 3 yrs) + AI ≥ 5 yrs
      vs AI alone
  - Broad inclusion → more “real-world” than monarchE
5-Year Update (ESMO 2025 / latest analyses):
- Efficacy (key numbers):
- iDFS HR ~0.72 → ~ 28% relative risk reduction
- 5-year iDFS:
  - 85.5% (ribociclib) vs 81.0% (ET alone):
    - Absolute benefit ~ 4.5%
  - Benefit persists after stopping drug (3-year exposure):
    - Indicates true disease-modifying effect
- Other endpoints:
  - ↓ Distant recurrence (DDFS HR ~0.71)
  - ↓ DRFS / RFS consistently improved
  - OS trend positive but immature
- Important nuance:
  - Absolute benefit increases over time (3 → 5 yrs):
    - Supports late recurrence suppression
Indications (current clinical positioning):
- Regulatory / guideline-aligned use:
- Adjuvant therapy with AI for:
  - HR+ / HER2− early breast cancer
  - Stage II to III at high risk of recurrence
  - “High-risk” (NATALEE definition):
    - Includes:
      - Stage IIB to III or
      - Stage IIA with N+ or
      - N0 + high-risk biology (e.g., Ki-67 ≥ 20%, grade 3, genomic risk)
Unique positioning vs abemaciclib:
- Broader population:
  - Includes:
    - Node-negative high-risk
    - Lower tumor burden
    - Lower starting dose → better tolerability strategy
Practical Implications for Breast Surgeons:
- Expands “systemic adjuvant” discussion at MDT
- You now need to identify patients who may benefit before finalizing adjuvant plan:
  - Candidates to flag early:
  - Stage II (even N0) with:
    - High grade
    - High Ki-67
    - Genomic high risk
  - Any Stage III HR+ disease
Impacts surgical-pathologic reporting priorities:
- Surgeons should ensure:
  - Accurate nodal staging
  - Grade
  - Ki-67
  - Genomic assay (if used) integrated early
    - These directly influence eligibility for CDK4/6 therapy
Reinforces importance of recurrence biology:
- Luminal cancers:
  - Long natural history
  - Late relapse risk
  - Ribociclib addresses micrometastatic dormancy
    → shifts mindset from:
    “Local control + endocrine therapy”
    → to
    “Extended systemic control strategy”
Treatment duration considerations:
- Ribociclib:
  - 3 years
- Endocrine therapy:
  - ≥ 5 years
Implication:
- Long-term adherence planning begins at surgical consultation
Safety Profile (surgeon-relevant highlights):
- Common:
  - Neutropenia (non-febrile)
  - LFT elevation
  - QT prolongation
- No new long-term safety signals at 5 years
- Clinical takeaway:
  - Manageable → supports use in early-stage curative setting
Key Takeaways for Surgical Practice:
- Ribociclib is now a standard adjuvant option in HR+/HER2− EBC:
  - Especially stage II to III and biologically high-risk disease
- 5-year data confirms durability:
  - Benefit persists beyond treatment window:
    - Increasing absolute benefit over time
- Expands eligible population:
  - Includes node-negative high-risk patients
- Multidisciplinary coordination is critical:
  - Surgeons play a role in:
    - Early identification
    - Pathologic risk stratification
    - Timely referral to medical oncology
Bottom line (surgeon-focused):
- Ribociclib from NATALEE represents a shift toward proactive systemic prevention of recurrence in luminal breast cancer, with durable 5-year benefit and broader eligibility than prior CDK4/6 strategies—making early risk identification at the surgical stage increasingly important